Bayer urges court to approve $7.25 billion Monsanto Roundup settlement that could limit its future liabilities Western Producer | September 14, 2026 (++)

https://geneticliteracyproject.org/2026/09/14/bayer-urges-court-to-approve-7-25-billion-monsanto-roundup-settlement-that-could-limit-its-future-liabilities/ Bayer is asking a Missouri court to grant final approval to a $7.25 billion settlement covering roughly 65,000 lawsuits claiming Roundup weedkiller causes non-Hodgkin lymphoma, as Reuters’ Dietrich Knauth reports. Judge Timothy Boyer heard arguments in St. Louis on September 14, 2026 but isn’t expected to rule immediately. ‘Glyphosate is not carcinogenic’: Independent EU chemical oversight agency reaffirms—for the 3rd time in 9 years—that the herbicide is safe-as-used Food Safety Magazine | September 14, 2026 https://geneticliteracyproject.org/2026/09/14/glyphosate-is-not-carcinogenic-independent-eu-chemical-oversight-agency-reaffirms-for-the-3rd-time-in-9-years-that-the-herbicide-is-safe-as-used/ The European Chemicals Agency’s Risk Assessment Committee (RAC) has reaffirmed, for the third time in nine years, that glyphosate does not warrant a carcinogen classification, even after reviewing new tumor data, as Food Safety Magazine’s Bailee Henderson reports. The September 8, 2026 decision upholds RAC’s 2022 hazard assessment and a 2023 EU risk review that found no critical health concerns tied to the world’s most widely used herbicide.

Hands-off: Trump rejects calls by AI leaders to increase regulation and slow development, citing Chinese competition Washington Post | September 14, 2026

https://geneticliteracyproject.org/2026/09/14/hands-off-trump-rejects-calls-by-ai-leaders-to-increase-regulation-and-slow-development-citing-chinese-competition/ President Donald Trump on September 13, 2026, brushed off calls from three top AI leaders — Anthropic’s Dario Amodei, OpenAI’s Sam Altman, and xAI’s Elon Musk — to slow the pace of AI development, insisting the US can’t afford to cede ground to China, as The Washington Post’s Cat Zakrzewski reports.

“Hit the brakes”: Anthropic warns the race to superintelligence could spawn internet-seizing AI swarms—and empower authoritarians. Here’s how to stop it. Dario Amodei | September 14, 2026

“Hit the brakes”: Anthropic warns the race to superintelligence could spawn internet-seizing AI swarms—and empower authoritarians. Here’s how to stop it. Dario Amodei | September 14, 2026 https://geneticliteracyproject.org/2026/09/14/hit-the-brakes-anthropic-warns-the-race-to-superintelligence-could-spawn-internet-seizing-ai-swarms-and-empower-authoritarians-heres-how-to-stop-it/ Ihave worked on AI for the last twelve years because I believe it could dramatically raise the quality of human life. I’ve written often about these incredible benefits: I believe that AI could cure most major diseases in the next 5–10 years, greatly accelerate economic growth rates, create a world of abundance and empowerment, and usher in a renaissance of democracy and freedom. I feel the urgency personally. My own father died of a disease that was cured just a few years after his death, and I myself survived an early-stage cancer that would not have been treatable even fifty years ago. Carefully wielded, AI can be the latest in a long line of technological miracles that have uplifted and ennobled humanity.

Restoring public trust in science doesn’t have a simple solution. That’s OK A problem this complex demands a broad lens, humility, and silo-busting

https://www.statnews.com/2026/09/14/trust-in-science-academia-research-communication-listening/ By Michelle Groman and Caroline MontojoSept. 14, 2026 Groman is president and CEO of The Greenwall Foundation. Montojo is president and CEO of the Dana Foundation.

Keeping breakthroughs moving Why the biggest opportunities to accelerate drug development lie between development stages Produced by STAT Brand Studio

https://www.statnews.com/sponsor/2026/09/14/keeping-breakthroughs-moving/

Trump’s secretive pharma deals may undermine ‘most-favored nation’ pricing, an analysis suggests The projected savings may be reduced by as much as 80%

https://www.statnews.com/2026/09/13/trump-secretive-pharma-deals-undermine-most-favored-nation-pricing/?utm_campaign=the_readout&utm_medium=email&_hsenc=p2ANqtz-8enpNwWiA9SMsuHayTEpFKB5dgEObPOqrpiomgHYm2Mio60RBWp3Sw2q8r36lw0vKYu-PFN9myZsUH4GYfuYEdoWkNxA&_hsmi=438904019&utm_content=438904019&utm_source=hs_email By Ed SilvermanSept. 13, 2026 Pharmalot Columnist, Senior Writer Drugmaker deals could gut Medicare drug savings Secretive deals between the Trump administration and 26 drugmakers could cut projected savings from its Medicare drug pricing pilots by as much as 80%, a new Lancet study shows. The administration’s GLOBE and GUARD programs would link Medicare payments to lower drug prices in 19 other wealthy countries, STAT’s Ed Silverman writes. But separate agreements with pharmaceutical companies could exempt many medicines from these reductions. Researchers estimated the programs could otherwise save Medicare $11.6 billion, but said the exemptions to drugmakers could dramatically erode any gains. “The administration deserves credit because it designed a pathway to deliver MFN pricing, but the implementation will be totally confounded by these side deals around which we have zero transparency,” said Thomas Hwang, the lead author of the study and an assistant professor of medicine at Brigham and Women’s Hospital in Boston.

GSK touts lung cancer data from two drugs

FDA panel confronting peptide controversy You’re reading STAT’s Readout newsletter https://www.statnews.com/2026/07/23/health-policy-news-today-dc-diagnosis-newsletter-john-wilkerson-2/?utm_campaign=the_readout&utm_medium=email&_hsenc=p2ANqtz-9kun-OCNmvZQs8LoxJp32FSuPqRJn05k9v-0ZsLjsEQiI7XSH6Fn5uS6A6Fw9Spy_f358tO9JeqEfL3EsL6r_ZS6-Itw&_hsmi=438904019&utm_content=438904019&utm_source=hs_email GSK touts lung cancer data from two drugs GSK plans to ask the FDA to expand the approval of its lung cancer drug Jideytro after presenting new data showing the targeted therapy produced durable responses in the majority of patients. The FDA authorized Jideytro in July for patients with non-small cell lung cancer with an ROS1 mutation who had already had been treated with a tyrosine kinase inhibitor. The new data came from a study of Jideytro as a first-line therapy. The ARROS-1 trial saw a 94% objective response rate, with the median duration of response and median progression-free survival not yet reached at the cutoff point, according to data presented at the World Conference on Lung Cancer in Seoul. The drug also helped shrink brain metastases in patients whose cancer had spread. GSK picked up Jideytro, known as zidesamtinib, through its acquisition of Nuvalent, as the U.K. firm has stepped up its return to oncology. Also at WCLC, Hansoh Pharmaceutical Group detailed strong data for the ADC ris-rez in a form of difficult-to-treat small cell lung cancer, showing that it reduced the risk of death as a second-line treatment. GSK has licensed global rights for ris-rez rights. Hansoh’s study took place in China, and there are outstanding questions about how instructive data from trials that solely take place in China are for the results of global trials that will be required by regulators in other parts of the world. But analysts say the ris-rez data released so far are promising for the medicine’s prospects. “We're really starting to see the emergence of what is probably the start of a franchise for GSK oncology and lung cancer,” Hesham Abdullah, the head of GSK’s oncology R&D, told reporters. Nuvalent says its ROS1-targeted drug shrank lung tumors in patients who failed other options The company hopes its non-small cell lung cancer drug will be used where predecessors have not https://www.statnews.com/2025/06/24/nuvalent-lung-cancer-ros1-zidesamtinib/?utm_campaign=the_readout&utm_medium=email&_hsenc=p2ANqtz-8Tsobhw9kX8rfiH8Xp9IEw_Or-xLam8Wv4W6WcPaHX5e8012fIknDwOImDheKv0My2pqUXDFMxhQN3kK04_c7azx8WfA&_hsmi=438904019&utm_content=438904019&utm_source=hs_email GSK to buy Nuvalent, maker of targeted cancer drugs, for $10.6B The move will grow the U.K. firm’s work in oncology, particularly in lung cancer https://www.statnews.com/2026/06/09/gsk-nuvalent-acquistion-oncology-lung-cancer-zidesamtinib-neladalkib/?utm_campaign=the_readout&utm_medium=email&_hsenc=p2ANqtz-_X6Y6EM22y3LdsAlam5G8LKiGBX4COyFF-BN1HagJu2H_X58_wFgF1pm80CWuKXI4QzRJldmRZXXVzkPkdH_e1Ly0K6g&_hsmi=438904019&utm_content=438904019&utm_source=hs_email